Molecular CellBiochemistryPeer-reviewed journal article
Filament formation activates protease and ring nuclease activities of CRISPR SAVED-Lon
Dalia SmalakytėiD, Audronė RukšėnaitėiD, Giedrius SasnauskasiD, Giedrė TamulaitienėiD, Gintautas TamulaitisiD
Abstract
To combat phage infection, type III CRISPR-Cas systems utilize cyclic oligoadenylates (cAn) signaling to activate various auxiliary effectors, including the CRISPR-associated SAVED-Lon protease CalpL, which forms a tripartite effector system together with an anti-{sigma} factor, CalpT, and an ECF-like {sigma} factor, CalpS. Here we report the characterization of the Candidatus Cloacimonas acidaminovorans CalpL-CalpT-CalpS. We demonstrate that cA4 binding triggers CalpL filament formation and activates it to cleave CalpT within the CalpT-CalpS dimer. This cleavage exposes the CalpT C-degron, which targets it for further degradation by cellular proteases. Consequently, CalpS is released to bind to RNA polymerase, causing growth arrest in E. coli. Furthermore, the CalpL-CalpT-CalpS system is regulated by the SAVED domain of CalpL, which is a ring nuclease that cleaves cA4 in a sequential three-step mechanism. These findings provide key mechanistic details for the activation, proteolytic events, and regulation of the signaling cascade in the type III CRISPR-Cas immunity.
- Citations
- 18
- FWCI
- 2.07
- Field percentile
- top 11%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The SAVED domain of the type III CRISPR protease CalpL is a ring nuclease
Sophie C. Binder, Niels Schneberger, … Gregor Hagelueken·Nucleic Acids ResearchPeer-reviewed·Jul 24, 2024
- A viral SAVED protein with ring nuclease activity degrades the CRISPR second messenger cA4
Marta Orzechowski, Ville Hoikkala, … Malcolm F. White·Biochemical JournalPeer-reviewed·Nov 1, 2025
- SAVED by a toxin: Structure and function of the CRISPR Lon protease.
C. Rouillon, N. Schneberger, … G. Hagelueken·bioRxiv·Dec 6, 2021
- Type III-B CRISPR-Cas signaling-based cascade of proteolytic cleavages
J. Steens, J. P. Bravo, … R. Staals·bioRxiv·Jun 23, 2023
- A CARF-HAD phosphatase effector provides immunity during the type III-A CRISPR-Cas response
Gianna Stella, Linzhi Ye, … Luciano A. Marraffini·Nucleic Acids ResearchPeer-reviewed·Nov 26, 2025
- The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling
J. S. Athukoralage, S. Grüschow, … M. F. White·bioRxiv·Feb 12, 2020